Prescient Therapeutics (ASX-PTX)
Live Investor Briefing
Register for an upcoming webcast
Please join us for a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke.
Steven will discuss:
- The company’s promising pipeline of cancer treatments with two targeted therapies, cell therapy enhancements and CAR-T
- Its work in the most exciting area of cancer research “next gen” CAR-T and its OmniCAR platform
- Strong balance sheet with $20m in the bank following oversubscribed Share Purchase Plan and Placement
This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.
Book Your Spot
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.
What is a 708 investor?FEATURE SPEAKER
Steven Yatomi Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.